We are live on ! Find out more
CCM

Consonance Capital Management Portfolio holdings

AUM $7.28M
1-Year Est. Return 43.59%
This Fund
S&P 500
This Quarter Est. Return
-20.85%
1 Year Est. Return
-43.59%
3 Year Est. Return
+313.86%
5 Year Est. Return
+886.32%
10 Year Est. Return
–
AUM
$711M
AUM Growth
-$285M
Cap. Flow
-$66.8M
Cap. Flow %
-9.4%
Top 10 Hldgs %
83.62%
Holding
33
New
5
Increased
15
Reduced
7
Closed
4

Top Buys

Rank Stock Value
1
VNDA icon
Vanda Pharmaceuticals
VNDA
+$17.6M
2
OSIR
Osiris Therapeutics, Inc. Common Stock
OSIR
+$16.6M
3
EGRX
Eagle Pharmaceuticals, Inc.
EGRX
+$14.2M
4
INSY
Insys Therapeutics, Inc.
INSY
+$10M
5
ABBV icon
AbbVie
ABBV
+$9.57M

Top Sells

Rank Stock Value
1
UTHR icon
United Therapeutics
UTHR
+$67.4M
2
ENTA icon
Enanta Pharmaceuticals
ENTA
+$28.8M
3
CLVS
Clovis Oncology, Inc.
CLVS
+$22.3M
4
CLDX icon
Celldex Therapeutics
CLDX
+$19M
5
TVTY
Tivity Health, Inc. Common Stock
TVTY
+$12.1M

Sector Composition

Rank Sector Weight
1 Healthcare 84.53%
2 Technology 0.52%
3 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
EGRX
1
DELISTED
Eagle Pharmaceuticals, Inc.
EGRX
$100M 14.1%
1,353,913
+170,507
+14% +$14.2M
INSY
2
DELISTED
Insys Therapeutics, Inc.
INSY
$92.7M 13.04%
3,257,094
+273,000
+9% +$10M
ABBV icon
3
AbbVie
ABBV
$458B
$78.7M 11.07%
1,445,900
+147,000
+11% +$9.57M
TVTX icon
4
Travere Therapeutics
TVTX
$5.33B
$69.9M 9.84%
3,450,323
+50,000
+1% +$1.48M
OFIX icon
5
Orthofix Medical
OFIX
$455M
$60.3M 8.48%
1,786,535
+60,838
+4% +$2.17M
AKRX
6
DELISTED
Akorn Inc
AKRX
$53.4M 7.52%
1,873,756
+30,000
+2% +$1.24M
ANIP icon
7
ANI Pharmaceuticals
ANIP
$1.77B
$41.7M 5.87%
1,056,289
+498
+0% +$28.3K
OSIR
8
DELISTED
Osiris Therapeutics, Inc. Common Stock
OSIR
$37.6M 5.29%
2,035,709
+859,514
+73% +$16.6M
CSII
9
DELISTED
Cardiovascular Systems, Inc.
CSII
$36.9M 5.19%
2,326,748
-149,539
-6% -$3.77M
PACB icon
10
Pacific Biosciences
PACB
$422M
$22.9M 3.22%
6,257,861
+859,000
+16% +$4.2M
ENTA icon
11
Enanta Pharmaceuticals
ENTA
$372M
$20.6M 2.9%
570,662
-670,659
-54% -$28.8M
CPRX
12
DELISTED
Catalyst Pharmaceutical
CPRX
$17.4M 2.45%
5,802,885
+285,000
+5% +$1.23M
VNDA icon
13
Vanda Pharmaceuticals
VNDA
$312M
$16.2M 2.28%
+1,436,796
New +$17.6M
EPRS
14
DELISTED
EPIRUS BIOPHARMACEUTICALS INC COM
EPRS
$10.3M 1.45%
2,324,669
+58,681
+3% +$345K
DSCI
15
DELISTED
Derma Sciences, Inc. Common Stock (DE)
DSCI
$8.92M 1.25%
1,893,467
+132,818
+8% +$858K
ADMA icon
16
ADMA Biologics
ADMA
$1.92B
$8.8M 1.24%
1,052,142
+17,421
+2% +$161K
NSTG
17
DELISTED
NanoString Technologies, Inc.
NSTG
$7.19M 1.01%
449,325
– –
VCEL icon
18
Vericel Corp
VCEL
$2.3B
$6.38M 0.9%
2,352,940
– –
CLVS
19
DELISTED
Clovis Oncology, Inc.
CLVS
$4.16M 0.58%
45,183
-257,948
-85% -$22.3M
SPNE
20
DELISTED
SeaSpine Holdings Corporation Common Stock
SPNE
$4.03M 0.57%
+248,502
New +$4.06M
IMPR
21
DELISTED
IMPRIVATA, INC COM
IMPR
$3.67M 0.52%
206,448
+110,689
+116% +$1.98M
MSLI
22
DELISTED
Merus Labs International Inc.
MSLI
$1.68M 0.24%
1,303,484
-338,104
-21% -$671K
LCTX icon
23
Lineage Cell Therapeutics
LCTX
$257M
$1.62M 0.23%
668,620
-143,602
-18% -$372K
VCYT icon
24
Veracyte
VCYT
$4.52B
$1.25M 0.18%
266,794
-32,172
-11% -$306K
BIOL
25
DELISTED
Biolase, Inc.
BIOL
$1.04M 0.15%
92
+39
+74% +$725K
1
2

Similar funds

GPC
Garrison Point Capital Walnut Creek, California $6.82M AUM 21.38% 1-Year Est. Return
BPM
Bronson Point Management Fairfield, Connecticut $8.26M AUM 46.43% 1-Year Est. Return
TVPI
True Venture Partners IV Palo Alto, California $8.41M AUM 78.89% 1-Year Est. Return
DCI
Data Collective II Palo Alto, California $8.44M AUM 11.7% 1-Year Est. Return
TPMI
Tilden Park Management I New York $5.38M AUM 28.49% 1-Year Est. Return
TP
Truvvo Partners New York $5.22M AUM 13.74% 1-Year Est. Return
SCG
Siris Capital Group New York $9.42M AUM 42.79% 1-Year Est. Return
CVGI
Craft Ventures GP I San Francisco, California $9.51M AUM 95.77% 1-Year Est. Return

Consonance Capital Management's Q3 2015 Portfolio in Review

As of Q3 2015, Consonance Capital Management held 33 positions worth $711M, down 29% from $995M the previous quarter. Its ten largest holdings account for 84% of the portfolio.

Consonance Capital Management withdrew a net $66.8M in Q3 2015, closing 4 positions and reducing 7 holdings. Its most notable exit was United Therapeutics, an estimated $67.4M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 85% of assets, up from 83% a quarter earlier, followed by Technology and Financials.

Against the trend, Consonance Capital Management opened a new position in Vanda Pharmaceuticals worth $16.2M.

  • Consonance Capital Management's largest Q3 2015 buy was Vanda Pharmaceuticals: 1,436,796 shares worth $16.2M.
  • Consonance Capital Management added most to Osiris Therapeutics, Inc. Common Stock in Q3 2015, an estimated $16.6M increase.
  • Consonance Capital Management's biggest Q3 2015 reduction was Enanta Pharmaceuticals, cutting an estimated $28.8M.
  • Consonance Capital Management fully exited United Therapeutics in Q3 2015, selling an estimated $67.4M.
  • Consonance Capital Management's ten largest holdings make up 84% of its $711M portfolio in Q3 2015.
  • Consonance Capital Management opened 5 new positions and closed 4 in Q3 2015.
  • Consonance Capital Management's portfolio value fell 29% quarter-over-quarter to $711M.

Based on Consonance Capital Management's 13F filing for Q3 2015, filed 9 Nov 2015.